Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Inotiv investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact inf

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) investors concerning the Company's possible violations of federal securities laws. On May 20, 2022, Inotiv disclosed that, after executing a search and seizure warrant at one of the Company's facilities, the U.S. Department of Justice filed a complaint alleging violations of the Animal Welfare Act at Inotiv's Cumberland, Virginia facilit

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 20, 2022, Inotiv disclosed that, after executing a search and seizure warrant at one of the Company's facilities, the U.S. Department of Justice filed a complaint alleging v

The Law Offices of Frank R. Cruz Continues Its Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inotiv, Inc. ("Inotiv" or "the Company") (NASDAQ: NOTV) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Inotiv files a Form 8-K with the SEC on May 20, 2022,...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Inotiv, Inc. with Losses of $100,000 to Contact the Firm

WEST LAFAYETTE, Ind., June 13, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announces the closure of two Envigo RMS (“Envigo”) facilities in Virginia: a purpose-bred canine facility in Cumberland and a rodent breeding facility in Dublin as part of restructuring activities following its acquisition of Envigo RMS LLC in November 2021.

Inotiv, Inc. Announces Site Closures and Consolidation Plans

Los Angeles, California--(Newsfile Corp. - May 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inotiv, Inc. ("Inotiv" or "the Company") (NASDAQ: NOTV) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Inotiv files a Form 8-K with the SEC on May 20, 2022,...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Inotiv, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of Inotiv stockholders. Our investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 20, 2022, Inotiv disclosed in a filing with the U.S. Securities and Ex

INOTIV ALERT: Bragar Eagel & Squire, P.C. is Investigating Inotiv, Inc. on Behalf of Inotiv Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices. Inotiv provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract r

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Inotiv, Inc. (NOTV) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Inotiv investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inotiv, Inc. (NASDAQ: NOTV) resulting from allegations that Inotiv may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Inotiv securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose

EQUITY ALERT: Rosen Law Firm Encourages Inotiv, Inc. Investors with Losses to Inquire About Class Action Investigation – NOTV

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) investors concerning the Company's possible violations of federal securities laws. On May 20, 2022, Inotiv disclosed that, after executing a search and seizure warrant at one of the Company's facilities, the U.S. Department of Justice filed a complaint alleging violations of the Animal Welfare Act at Inotiv's Cumberland, Virginia facility

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 20, 2022, Inotiv disclosed that, after executing a search and seizure warrant at one of the Company's facilities, the U.S. Department of Justice filed a complaint alleging vi

The Law Offices of Frank R. Cruz Announces Investigation of Inotiv, Inc. (NOTV) on Behalf of Investors

Inotiv, Inc. (NASDAQ:NOTV ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Kalle Ahl - The Equity Group Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to Inotiv, Incorporated's Second Quarter Fiscal 2022 Financial Results conference call.

Inotiv, Inc. (NOTV) CEO Bob Leasure on Q2 2022 Results - Earnings Call Transcript

WEST LAFAYETTE, Ind., May 12, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2022”) and six months (“H1 FY 2022”) ended March 31, 2022.

Inotiv, Inc. Announces Second Quarter Fiscal 2022 Financial Results

WEST LAFAYETTE, Ind., April 26, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 second quarter ended March 31, 2022, on Thursday, May 12, 2022, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Second Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, May 12, 2022

WEST LAFAYETTE, Ind., April 25, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the acquisition of Histion, LLC (“Histion”), effective April 25, 2022. The acquisition is a strategic element of the Company's expansion of its specialized pathology services.

Inotiv, Inc. Bolsters Pathology Services with Acquisition of Histion, LLC

Primis Financial Corp.

James River Group Holdings

Reservoir Media

Utz Brands

According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months include Primis Financial Corp. ( FRST , Financial), James River Group Holdings Ltd. ( JRVR , Financial), Reservor Media Inc. ( RSVR , Financial), Utz Brands Inc. ( UTZ , Financial) and Inotiv Inc. ( NOTV , Financial).

5 Stocks Insiders Are Charging Up for Spring

Cardiovascular Systems

Nuvectis Pharma

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

3 Moonshot Stocks Insiders Are Buying. What Do They Know?

Inotiv, Inc. (NOTV) CEO Bob Leasure on Q1 2022 Results Earnings Call Transcript

WEST LAFAYETTE, Ind., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ended December 31, 2021 (“Q1 FY 2022”).

Inotiv, Inc. Announces First Quarter Fiscal 2022 Financial Results

Inotiv is a leading mid-market CRO offering a full suite of non-clinical services. The Company has been on an acquisition spree, latest being Envigo, upping its game to full programs.

Inotiv: Leading Mid-Market CRO Ups Its Game

WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 first quarter ended December 31, 2021, on Thursday, February 10, 2022, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report First Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, February 10, 2022

WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company has completed the purchase of Orient BioResource Center, Inc. (“OBRC”), from Orient Bio, Inc., a preclinical contract research organization and animal model supplier based in Seongnam, South Korea. Orient BioResource Center is a primate quarantine and holding facility located near Alice, Texas.

Inotiv, Inc. Announces Expansion of Non-Human Primate Facilities and Services with Acquisition of Orient BioResource Center, Inc.

Inotiv, Inc. (NOTV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Inotiv, Inc. (NOTV) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

WEST LAFAYETTE, Ind., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company has completed the purchase of Integrated Laboratory Systems, LLC (“ILS”), a portfolio company of Sier Capital Partners (“Sier Capital”). ILS is a contract research organization, located in Morrisville, North Carolina, specializing in genetic toxicology, in vivo and in vitro toxicology, pathology, molecular biology, bioinformatics and computational toxicology services.

News for Inotiv, Inc. Stock (NOTV)